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Background: Nonalcoholic fatty liver disease (NAFLD) has a high prevalence in the general 
population and is the most common liver disease in Western countries. It is a feature of metabolic 
syndrome and is characterized by excessive accumulation of fat in the liver cells.
Methods: We examined 84 consecutive middle-aged (under 45 years) patients with NAFLD 
and 65 control subjects matched for age, gender, and body mass index to determine carotid 
intima-media thickness (CIMT) and flow-mediated dilatation (FMD) in the brachial artery.
Results: There was a statistically significant difference between CIMT and percentage increase 
in FMD in the patient group (P = 0.002; r = 0.33) when compared with the control group 
(P = 0.97; r = 0.005). The mean ± standard deviation CMIT was 0.65 ± 0.09 mm in patients 
and 0.55 ± 0.07 mm in controls. This difference was statistically significant (P = 0.001). Mean 
FMD in patients was 6.4% and 15.7% in controls. This difference was statistically significant 
(P = 0.001).
Conclusion: This study shows that pure NAFLD without metabolic syndrome in middle-aged 
subjects is strongly associated with morphological (CIMT) and physiological (FMD) changes. 
These findings may have an important role in increasing cardiovascular risk in these patients.
Keywords: nonalcoholic fatty liver disease, carotid intima-media thickness, flow-mediated 
dilatation
Introduction
Nonalcoholic fatty liver disease (NAFLD) has a high prevalence in the general 
population and is the most common liver disease in Western countries.1 It is one of 
the features of metabolic syndrome and is characterized by excessive accumulation 
of fat in the liver cells.2,3 Patients with NAFLD have a higher mortality rate compared 
with the general population.4
NAFLD is also strongly associated with risk factors for atherosclerosis, such as 
obesity, dyslipidemia, hypertension, type 2 diabetes mellitus, and insulin resistance.5 
NAFLD has been recently accepted as a hepatic component of metabolic syndrome.6 
In published data, the mortality rate for coronary heart disease in patients with 
NAFLD is equal to the mortality related to cirrhosis.7 Theoretically, the increased risk 
of cardiovascular events in patients with NAFLD is due to coexistence of this entity 
with metabolic syndrome. Ultrasonographic measurement of flow-mediated dilatation 
(FMD) is a noninvasive method to demonstrate subclinical atherosclerosis,8 with recent 
data showing it to be a predictor of cardiovascular events.9,10 There are no published data 
regarding the association between NAFLD and subclinical atherosclerosis in middle-





of middle-aged patients with ultrasonographically confirmed 
NAFLD. The novelty of our research is that it evaluated ath-
erosclerotic findings in middle-aged patients with NAFLD and 
without metabolic syndrome. We wanted to demonstrate that 
atherosclerosis can affect vascular anatomy and physiology 
in NAFD patients, independent of other risk factors. FMD 
could serve as an important marker for early introduction of 
a cardioprotective protocol in NAFLD patients.
Materials and methods
We enrolled 84 consecutive middle-aged (30–45 years) 
patients with NAFLD and 65 controls matched for age, 
  gender, and body mass index to determine carotid intima-
media thickness (CIMT) and FMD of the brachial artery. 
The study protocol was approved by the University Ethics 
Committee and the Faculty of Medicine. Written informed 
consent was obtained from all participants.
Diagnosis of NAFLD was made on the basis of 
  ultrasonographic criteria. Abdominal ultrasound scanning 
was performed in all participants by one trained radiologist 
who was blinded to all clinical and laboratory data, using a 
Toshiba Nemio 30 scanner (Toshiba Co Ltd, Tokyo, Japan) 
with a 3.5 mHz linear transducer. Hepatic steatosis was 
diagnosed by a characteristic liver echo pattern (diffuse 
hyperechogenicity of liver compared with right kidney).
Subjects  with  heart  disease,  diabetes  mellitus, 
hypertension (blood pressure .130/85 mmHg), hyperlipi-
demia, acute or chronic liver disease, acute or chronic kidney 
disease, any malignancy, alcohol consumption, pregnancy, 
liver masses, abnormal copper metabolism or thyroid func-
tion test, taking any medication with adverse effects on liver 
or cardiovascular system, history of cigarette smoking, or 
criteria of metabolic syndrome were excluded. Only patients 
negative for hepatitis B surface antigen and hepatitis C anti-
body were enrolled. Subjects with a body mass index above 
30 kg/m2 were also excluded. At the time of the study, the 
NAFLD patients had no clinical or biochemical evidence 
of liver cirrhosis.
Blood samples were collected in the   morning 
after overnight fasting for biochemical measurements. 
Biochemical inclusion criteria were fasting blood glu-
cose ,110 mg/dL,   triglycerides ,150 mg/dL, total choles-
terol ,240 mg/dL, high-density lipoprotein .40 mg/dL for men 
and .50 mg/dL for women, and serum transaminases (alanine 
aminotransferase, normal adult range 8–20 U/L, aspartate ami-
notransferase, normal adult range 8–20 U/L). All biochemical 
investigations were performed in the same laboratory.
Ultrasonographic examination of FMD was performed 
in the morning after an overnight fast and 15 minutes of rest 
in the horizontal position, using a Sonoline G40   ultrasound 
scanner (Siemens, Germany) with a 10 mHz   linear transducer. 
The diameter of the right brachial artery was measured 3–5 cm 
above the antecubital space at   baseline. The   measurements 
were performed in the end-diastolic phase, marking the 
diameter between the anterior and posterior artery wall in the 
zone between the media and adventitia (M line, Figure 1). An 
average of three measurements was used to calculate FMD. 
A pneumatic tourniquet was subsequently placed on the upper 
part of the right forearm and inflated for four minutes to a 
pressure of 200 mmHg or 50 mmHg above systemic arterial 
blood pressure. Sixty seconds after the cuff was released, 
the diameter of the right brachial artery was measured three 
times. FMD was calculated as the percent increase in vascular 
diameter from the difference between the maximum and 
baseline brachial artery diameter.
The maximum CIMT was measured at the posterior wall 
of the common carotid artery, 2 cm before the bifurcation, 
as the distance between the first and second echogenic lines 
of the anterior and posterior arterial walls. The image was 
focused on the posterior wall of the common carotid artery, 
and gain settings were used to optimize image quality. 
Measurement was performed vertical to the arterial wall for 
accurate recording of CIMT. Three CIMT measurements 
were taken at each site and the average measurement was 
used (Figure 2).
Data were calculated as the absolute diameter of the 
  brachial artery (in mm) and the percent increase from baseline 
after cuff release and in response to ischemia.
Figure 1 Longitudinal ultrasonogram of the brachial artery diameter from anterior 




ciMT and FMD in patients with nAFLD
statistical analysis
Statistical analysis was performed using SPSS version 
16 (SPSS Inc, Chicago, IL). Data were expressed as the 
mean ± standard deviation (SD) for numerical variables. 
We also used the independent Chi-square test and t-test to 
analyze the data. P # 0.05 was considered to be statistically 
significant.
Results
Eighty-four patients with fatty liver disease and 65 age-
matched controls were enrolled in the study. Forty-four 
patients were male and 40 were female, and 35 of the 
controls were male and 30 were female. Mean age was 
37.71 ± 4.95 years in the patient group and 38.38 ± 4 years 
in the control group. There was no statistically significant 
difference between two groups with regard to age (P = 0.39). 
Forty-two patients had grade 1 (50%), 29 patients had grade 
2 (34.5%), and 13 patients (15.5%) had grade 3 fatty liver 
disease. There was a significant difference between CIMT 
and percent increase in FMD in patients (P = 0.002; r = 0.33) 
when compared with controls (P = 0.97; r = 0.005). The data 
for laboratory parameters, body mass index, age, and gender 
are presented in Table 1.
Mean CMIT was 0.65 ± 0.09 mm in patients and 
0.55 ± 0.07 mm in controls. This difference was statistically 
significant (P = 0.001). The mean increase in brachial artery 
diameter was 0.22 ± 0.11 mm in patients and 0.57 ± 0.13 mm 
in controls. This difference was statistically significant 
(P = 0.001), indicating an increase in diameter with ischemia. 
Mean brachial artery diameter at baseline was 3.9 ± 1.9 mm 
in patients and 3.8 ± 2.2 mm in controls. The difference 
was not statistically significant (P = 0.058). Mean brachial 
artery diameter in response to ischemia was 4.15 ± 1.9 mm 
in patients and 4.4 ± 2.2 mm in the controls. This differ-
ence was statistically significant (P = 0.001). Mean FMD 
in patients was 6.4% and 15.7% in controls. The difference 
was statistically significant (P = 0.001).
Discussion
Nonalcoholic fatty liver disease is defined as   excessive 
accumulation of fat in hepatocytes. NAFLD was   previously 
considered to be a benign disease without clinical 
consequences. Nowadays, it is known that NAFLD is 
associated with a range of pathologic lesions, ranging 
from simple steatosis to nonalcoholic steatohepatitis and 
cirrhosis. The prevalence of NAFLD in adults is estimated 
to be 20%–30% of the general population in Western 
countries11 and 12%–24% in Asian-Pacific countries.12 The 
prevalence in obese and diabetic patients increases up to 
70%–90%.11
NAFLD is strongly associated with cardiovascular 
risk factors, such as obesity, dyslipidemia, type 2 diabetes 
  mellitus, and insulin resistance.13 In the published data, 
mortality rates from coronary heart disease in patients with 
NAFLD were equal to those related to cirrhosis. NAFLD 
is now considered to be a hepatic manifestation of the 
  metabolic syndrome.5 It is well known that the metabolic 
syndrome represents a “tsunami” of cardiovascular risk fac-
tors. Our study shows that NAFLD, even in the absence of the 
metabolic syndrome, is associated with increased CIMT and 
endothelial dysfunction, which are the major determinants 
of cardiovascular events.
In understanding the true pathophysiologic basis of 
NAFLD, the chicken and egg phenomenon persists, in that 
some authors believe that NAFLD can produce insulin 
  resistance14 while others claim that insulin resistance is the 
major determinant of development and progression of fatty 
liver to nonalcoholic steatohepatitis.
The endothelium is considered to be the largest endocrine 
gland in the body, and secretes many transmitters to maintain 
homeostasis in the circulatory system.8 FMD is a noninvasive 
ultrasonographic method which is currently recognized 
as a useful technique for evaluating endothelial function.8 
The basic mechanism for FMD is to observe vasodilation 
by sonography after provoking ischemia by inflating blood 
pressure cuff. After brachial artery   occlusion, endothelial 
nitric oxide is released and vascular smooth muscle relax-
ation occurs.15
Figure 2 Longitudinal ultrasonogram of common carotid artery shows the carotid 





One of the early processes in the pathophysiology 
of atherosclerosis is impaired endothelial function.16 
Impaired endothelial function quantified by FMD is a marker 
of increased cardiovascular risk, due to its correlation with 
impaired endothelial function in the coronary arteries.17
Given that age, gender, and body mass index, as well 
as other cardiovascular risk factors, can influence the 
pathogenesis of atherosclerosis and its major determinants, 
ie, FMD and CIMT,18 we matched cases and controls to 
eliminate as far as possible the effect of old age on FMD 
and CIMT.
Our results are similar to those of Vlachopoulos et al18 
who showed that NAFLD is associated with arterial stiffness 
and impaired endothelial function. We showed that there is 
a strong association between CIMT which is a morphologi-
cal change and FMD which is a physiological change. Our 
study is similar to one reported by Glovinska-Olszewska 
et al,19,20 except that they showed the association in obese 
children and we demonstrated it in normotensive middle-
aged patients. The percentage FMD increase in our study 
is similar to that of Villanova et al,21 who reported that 
mean FMD in their patients with NAFLD was 6.33% and 
was 12.22% in   controls. However, our measurements are 
greater than those of  Vlachopoulos et al,18 who reported a 
mean FMD of 1.92% in patients with NAFLD and 4.8% 
in controls. This difference may be due to the age differ-
ence between patients in our study and those in their study, 
given that it is known that age is an important factor in 
CIMT and FMD.21 In conclusion, our study demonstrates 
that NAFLD without metabolic syndrome in middle-aged 
subjects is strongly associated with morphological (CIMT) 
and physiological (FMD) changes, and these findings may 
have a substantial role in increasing cardiovascular risk in 
patients with NAFLD.
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Table 1 Main clinical, ultrasonographic, and laboratory data for patients with nAFLD and control subjects
Group Mean SD 95% CI Significance  
(two-tailed)
Age case 38.71 4.952 -1.170 0.665
control 38.38 4.084 -1.134 0.657
ALT case 32.43 16.914 1.445 0.010
control 26.37 9.375 1.745 0.006
AsT case 20.50 8.076 -0.877 0.222
control 19.06 5.567 -0.774 0.201
FBs case 91.81 8.602 -1.277 0.297
control 90.37 7.948 -1.250 0.292
Tg case 104.67 20.884 -5.960 0.735
control 103.43 23.457 -6.076 0.739
cholesterol case 137.93 34.811 -18.723 0.114
control 146.28 27.348 -18.412 0.103
HDL case 49.06 6.337 -5.428 0.002
control 52.40 6.466 -5.434 0.002
ciMT case 0.640 0.0958 0.0581 0.000
control 0.554 0.0752 0.0589 0.000
increased in diameter case 0.2298 0.11384 -0.38290 0.000
control 0.5723 0.13522 -0.38385 0.000
BMi case 24.4545 1.27104 -0.12928 0.172
control 24.1614 1.32235 -0.13174 0.175
Brachial artery diameter prior to ischemia case 3.924 0.1911 -0.0023 0.058
control 3.858 0.2263 -0.0039 0.064
Brachial artery diameter after ischemia case 4.154 0.1997 -0.3464 0.000
control 4.431 0.2270 -0.3476 0.000
Abbreviations: CI, confidence interval; FBS, fasting blood glucose; TG, triglycerides; HDL, high-density lipoproteins; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; CIMT, carotid intima media thickness; BMI, body mass index; SD, standard deviation.Vascular Health and Risk Management
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